Skip to main content
. 2022 Aug 18;13:973880. doi: 10.3389/fimmu.2022.973880

Figure 2.

Figure 2

Effects of Tas2R126/135/143 agonists on CXCL2-induced neutrophil migration. (A) Transwell migration assays of bone marrow (BM)-derived neutrophils from wild-type C57BL/6 mice after pretreatment with the indicated concentrations of the Tas2R126/143 agonists arbutin and d-salicin or the Tas2R126 agonist PBD-Gluco for 30 min followed by stimulation with 20 ng/ml CXCL2. Data are presented as the mean ± SD of triplicates from one experiment and are representative of three independent experiments. *p < 0.05 by Student’s t test. (B) Transwell migration assays of BM-derived neutrophils from wild-type C57BL/6 mice after pretreatment with the Tas2R135 agonists denatonium and 5-propyl-2-thiouracil for 30 min followed by stimulation with 20 ng/ml CXCL2. Data are presented as the mean ± SD of triplicates from one experiment and are representative of three independent experiments. (C) FACS analysis of CXCR2 expression on purified neutrophils incubated with (red) or without (blue) arbutin. Gray histogram shows the isotype control-stained cells. Data are representative of three independent experiments.